Paion AG
Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and intensive care medicine services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation… Read more
Paion AG - Asset Resilience Ratio
Paion AG (PAIOF) has an Asset Resilience Ratio of 0.00% as of June 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2018)
This chart shows how Paion AG's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Paion AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Paion AG maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Paion AG Industry Peers by Asset Resilience Ratio
Compare Paion AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Paion AG (2014–2018)
The table below shows the annual Asset Resilience Ratio data for Paion AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-12-31 | 0.00% | $0.00 | $24.32 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $31.89 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $37.98 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $43.47 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $66.55 Million | -- |